Cargando…
Anti-Tumor Efficiency of Perillylalcohol/β-Cyclodextrin Inclusion Complexes in a Sarcoma S180-Induced Mice Model
The low solubility and high volatility of perillyl alcohol (POH) compromise its bioavailability and potential use as chemotherapeutic drug. In this work, we have evaluated the anticancer activity of POH complexed with β-cyclodextrin (β-CD) using three complexation approaches. Molecular docking sugge...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916601/ https://www.ncbi.nlm.nih.gov/pubmed/33578857 http://dx.doi.org/10.3390/pharmaceutics13020245 |
_version_ | 1783657514789765120 |
---|---|
author | Rezende, Allan A. Santos, Rafael S. Andrade, Luciana N. Amaral, Ricardo G. Pereira, Matheus M. Bani, Cristiane Chen, Mo Priefer, Ronny da Silva, Classius F. de Albuquerque Júnior, Ricardo L. C. Souto, Eliana B. Severino, Patrícia |
author_facet | Rezende, Allan A. Santos, Rafael S. Andrade, Luciana N. Amaral, Ricardo G. Pereira, Matheus M. Bani, Cristiane Chen, Mo Priefer, Ronny da Silva, Classius F. de Albuquerque Júnior, Ricardo L. C. Souto, Eliana B. Severino, Patrícia |
author_sort | Rezende, Allan A. |
collection | PubMed |
description | The low solubility and high volatility of perillyl alcohol (POH) compromise its bioavailability and potential use as chemotherapeutic drug. In this work, we have evaluated the anticancer activity of POH complexed with β-cyclodextrin (β-CD) using three complexation approaches. Molecular docking suggests the hydrogen-bond between POH and β-cyclodextrin in molar proportion was 1:1. Thermal analysis and Fourier-transform infrared spectroscopy (FTIR) confirmed that the POH was enclosed in the β-CD cavity. Also, there was a significant reduction of particle size thereof, indicating a modification of the β-cyclodextrin crystals. The complexes were tested against human L929 fibroblasts after 24 h of incubation showing no signs of cytotoxicity. Concerning the histopathological results, the treatment with POH/β-CD at a dose of 50 mg/kg promoted approximately 60% inhibition of tumor growth in a sarcoma S180-induced mice model and the reduction of nuclear immunoexpression of the Ki67 antigen compared to the control group. Obtained data suggest a significant reduction of cycling cells and tumor proliferation. Our results confirm that complexation of POH/β-CD not only solves the problem related to the volatility of the monoterpene but also increases its efficiency as an antitumor agent. |
format | Online Article Text |
id | pubmed-7916601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79166012021-03-01 Anti-Tumor Efficiency of Perillylalcohol/β-Cyclodextrin Inclusion Complexes in a Sarcoma S180-Induced Mice Model Rezende, Allan A. Santos, Rafael S. Andrade, Luciana N. Amaral, Ricardo G. Pereira, Matheus M. Bani, Cristiane Chen, Mo Priefer, Ronny da Silva, Classius F. de Albuquerque Júnior, Ricardo L. C. Souto, Eliana B. Severino, Patrícia Pharmaceutics Article The low solubility and high volatility of perillyl alcohol (POH) compromise its bioavailability and potential use as chemotherapeutic drug. In this work, we have evaluated the anticancer activity of POH complexed with β-cyclodextrin (β-CD) using three complexation approaches. Molecular docking suggests the hydrogen-bond between POH and β-cyclodextrin in molar proportion was 1:1. Thermal analysis and Fourier-transform infrared spectroscopy (FTIR) confirmed that the POH was enclosed in the β-CD cavity. Also, there was a significant reduction of particle size thereof, indicating a modification of the β-cyclodextrin crystals. The complexes were tested against human L929 fibroblasts after 24 h of incubation showing no signs of cytotoxicity. Concerning the histopathological results, the treatment with POH/β-CD at a dose of 50 mg/kg promoted approximately 60% inhibition of tumor growth in a sarcoma S180-induced mice model and the reduction of nuclear immunoexpression of the Ki67 antigen compared to the control group. Obtained data suggest a significant reduction of cycling cells and tumor proliferation. Our results confirm that complexation of POH/β-CD not only solves the problem related to the volatility of the monoterpene but also increases its efficiency as an antitumor agent. MDPI 2021-02-10 /pmc/articles/PMC7916601/ /pubmed/33578857 http://dx.doi.org/10.3390/pharmaceutics13020245 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rezende, Allan A. Santos, Rafael S. Andrade, Luciana N. Amaral, Ricardo G. Pereira, Matheus M. Bani, Cristiane Chen, Mo Priefer, Ronny da Silva, Classius F. de Albuquerque Júnior, Ricardo L. C. Souto, Eliana B. Severino, Patrícia Anti-Tumor Efficiency of Perillylalcohol/β-Cyclodextrin Inclusion Complexes in a Sarcoma S180-Induced Mice Model |
title | Anti-Tumor Efficiency of Perillylalcohol/β-Cyclodextrin Inclusion Complexes in a Sarcoma S180-Induced Mice Model |
title_full | Anti-Tumor Efficiency of Perillylalcohol/β-Cyclodextrin Inclusion Complexes in a Sarcoma S180-Induced Mice Model |
title_fullStr | Anti-Tumor Efficiency of Perillylalcohol/β-Cyclodextrin Inclusion Complexes in a Sarcoma S180-Induced Mice Model |
title_full_unstemmed | Anti-Tumor Efficiency of Perillylalcohol/β-Cyclodextrin Inclusion Complexes in a Sarcoma S180-Induced Mice Model |
title_short | Anti-Tumor Efficiency of Perillylalcohol/β-Cyclodextrin Inclusion Complexes in a Sarcoma S180-Induced Mice Model |
title_sort | anti-tumor efficiency of perillylalcohol/β-cyclodextrin inclusion complexes in a sarcoma s180-induced mice model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916601/ https://www.ncbi.nlm.nih.gov/pubmed/33578857 http://dx.doi.org/10.3390/pharmaceutics13020245 |
work_keys_str_mv | AT rezendeallana antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT santosrafaels antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT andradelucianan antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT amaralricardog antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT pereiramatheusm antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT banicristiane antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT chenmo antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT prieferronny antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT dasilvaclassiusf antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT dealbuquerquejuniorricardolc antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT soutoelianab antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel AT severinopatricia antitumorefficiencyofperillylalcoholbcyclodextrininclusioncomplexesinasarcomas180inducedmicemodel |